NASDAQ: ALZN
Linkedin Facebook-f Twitter Youtube Instagram
Alzamend Neuro, Inc.
  • About us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Scientific Advisory Board
  • Science
    • Product Pipeline
    • Publications
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
    • Contact Us
    • Careers
Menu
  • About us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Scientific Advisory Board
  • Science
    • Product Pipeline
    • Publications
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
    • Contact Us
    • Careers

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • In The News
    • IR Calendar
    • Email Alerts
  • Company Info
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Presentations
  • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • In The News
  • IR Calendar
  • Email Alerts
Nov 20, 2023 8:00am EST

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

Nov 16, 2023 8:00am EST

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Nov 13, 2023 8:00am EST

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001

Oct 30, 2023 8:00am EDT

Alzamend Neuro Announces Reverse Stock Split

Oct 23, 2023 8:00am EDT

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001

Oct 02, 2023 8:00am EDT

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Sep 22, 2023 8:00am EDT

Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

Aug 30, 2023 8:00am EDT

Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Jun 22, 2023 8:00am EDT

Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001

Jun 13, 2023 8:00am EDT

Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Making Alzheimer’s
Just a Memory™

About

  • Overview
  • Management
  • Board of Directors
  • Governance

Investor Relations

  • Overview
  • News & Events
  • Company Info
  • Presentations
  • Financial Results
  • Stock Data
  • SEC Filings
  • Governance

Other

  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Safe Harbor

© 2016-22 Alzamend Neuro, Inc. All rights reserved.

Linkedin Facebook-f Twitter Youtube Instagram
Skip to content